Literature DB >> 24641310

Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.

B Simonson1, A S Morani, A W M Ewald, L Walker, N Kumar, D Simpson, J H Miller, T E Prisinzano, B M Kivell.   

Abstract

BACKGROUND AND
PURPOSE: Acute activation of κ opioid (KOP) receptors results in anticocaine-like effects, but adverse effects, such as dysphoria, aversion, sedation and depression, limit their clinical development. Salvinorin A, isolated from the plant Salvia divinorum, and its semi-synthetic analogues have been shown to have potent KOP receptor agonist activity and may induce a unique response with similar anticocaine addiction effects as the classic KOP receptor agonists, but with a different side effect profile. EXPERIMENTAL APPROACH: We evaluated the duration of effects of Mesyl Sal B in vivo utilizing antinociception assays and screened for cocaine-prime induced cocaine-seeking behaviour in self-administering rats to predict anti-addiction effects. Cellular transporter uptake assays and in vitro voltammetry were used to assess modulation of dopamine transporter (DAT) function and to investigate transporter trafficking and kinase signalling pathways modulated by KOP receptor agonists. KEY
RESULTS: Mesyl Sal B had a longer duration of action than SalA, had anti-addiction properties and increased DAT function in vitro in a KOP receptor-dependent and Pertussis toxin-sensitive manner. These effects on DAT function required ERK1/2 activation. We identified differences between Mesyl Sal B and SalA, with Mesyl Sal B increasing the Vmax of dopamine uptake without altering cell-surface expression of DAT. CONCLUSIONS AND IMPLICATIONS: SalA analogues, such as Mesyl Sal B, have potential for development as anticocaine agents. Further tests are warranted to elucidate the mechanisms by which the novel salvinorin-based neoclerodane diterpene KOP receptor ligands produce both anti-addiction and adverse side effects. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  Salvia divinorum; addiction; cocaine self-administration; dopamine transporter; drug seeking; nociception; salvinorin A; κ opioid receptor

Mesh:

Substances:

Year:  2014        PMID: 24641310      PMCID: PMC4292965          DOI: 10.1111/bph.12692

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  91 in total

1.  Sensitization to cocaine's reinforcing effects produced by various cocaine pretreatment regimens in rats.

Authors:  S Schenk; B Partridge
Journal:  Pharmacol Biochem Behav       Date:  2000-08       Impact factor: 3.533

2.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

3.  The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.

Authors:  Aashish S Morani; Amy Ewald; Katherine M Prevatt-Smith; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

4.  Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors.

Authors:  Agustin Zapata; Bronwyn Kivell; Yang Han; Jonathan A Javitch; Elizabeth A Bolan; David Kuraguntla; Vanaja Jaligam; Murat Oz; Lankupalle D Jayanthi; Devadoss J Samuvel; Sammanda Ramamoorthy; Toni S Shippenberg
Journal:  J Biol Chem       Date:  2007-10-08       Impact factor: 5.157

5.  Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.

Authors:  F Simonin; O Valverde; C Smadja; S Slowe; I Kitchen; A Dierich; M Le Meur; B P Roques; R Maldonado; B L Kieffer
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

Review 6.  Novel GPCR paradigms at the μ-opioid receptor.

Authors:  G L Thompson; E Kelly; A Christopoulos; M Canals
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

7.  Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles.

Authors:  A L Svingos; C Chavkin; E E Colago; V M Pickel
Journal:  Synapse       Date:  2001-12-01       Impact factor: 2.562

Review 8.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

9.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

10.  Methods for intravenous self administration in a mouse model.

Authors:  Elizabeth K Kmiotek; Corey Baimel; Kathryn J Gill
Journal:  J Vis Exp       Date:  2012-12-08       Impact factor: 1.355

View more
  27 in total

1.  Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.

Authors:  Yan Zhou; Rachel Saylor Crowley; Konrad Ben; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2017-03-02       Impact factor: 3.252

2.  The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.

Authors:  K F Paton; N Kumar; R S Crowley; J L Harper; T E Prisinzano; B M Kivell
Journal:  Eur J Pain       Date:  2017-02-03       Impact factor: 3.931

3.  MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.

Authors:  Diana V Atigari; Rajendra Uprety; Gavril W Pasternak; Susruta Majumdar; Bronwyn M Kivell
Journal:  Neuropharmacology       Date:  2019-02-13       Impact factor: 5.250

Review 4.  A review of salvinorin analogs and their kappa-opioid receptor activity.

Authors:  Jeremy J Roach; Ryan A Shenvi
Journal:  Bioorg Med Chem Lett       Date:  2018-03-12       Impact factor: 2.823

5.  The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects.

Authors:  Amy W M Ewald; Peter J Bosch; Aimee Culverhouse; Rachel Saylor Crowley; Benjamin Neuenswander; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Psychopharmacology (Berl)       Date:  2017-05-23       Impact factor: 4.530

6.  Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice.

Authors:  Yan Zhou; Rachel Crowley; Thomas Prisinzano; Mary Jeanne Kreek
Journal:  Neurosci Lett       Date:  2018-02-26       Impact factor: 3.046

Review 7.  Involvement of Activated Brain Stress Responsive Systems in Excessive and "Relapse" Alcohol Drinking in Rodent Models: Implications for Therapeutics.

Authors:  Yan Zhou; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2018-04-18       Impact factor: 4.030

8.  Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.

Authors:  Alexander M Sherwood; Rachel Saylor Crowley; Kelly F Paton; Andrew Biggerstaff; Benjamin Neuenswander; Victor W Day; Bronwyn M Kivell; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2017-04-19       Impact factor: 7.446

Review 9.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

10.  A selective delta opioid receptor antagonist based on a stilbene core.

Authors:  Alyssa M Hartung; Hernan A Navarro; David F Wiemer; Jeffrey D Neighbors
Journal:  Bioorg Med Chem Lett       Date:  2015-10-23       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.